<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178164</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2010/04</org_study_id>
    <nct_id>NCT01178164</nct_id>
  </id_info>
  <brief_title>Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains</brief_title>
  <acronym>DOUFAB</acronym>
  <official_title>Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fabry disease (FD) is a rare X-linked multisytemic lysosomal disorder caused by&#xD;
      alpha-galactosidase deficiency. Globotriaosylc√©ramide (Gb3) deposits are observed in almost&#xD;
      all tissues examined. Signs of the disease appear earlier and are more severe in affected&#xD;
      males than in females. Myocardiopathy, renal failure and neurological signs including chronic&#xD;
      pain and peripheral neuropathies are the most frequent signs. The availability of two&#xD;
      enzymatic replacement therapies now provides a specific and effective treatment for patients.&#xD;
      The prevalence of FD is estimated between 1/40,000 and 1/117,000. The frequency of Fabry&#xD;
      disease has previously been estimated in several series of patients presenting one single&#xD;
      sign, ie renal failure, hypertrophic myocardiopathy and early onset stroke. However, no data&#xD;
      are available about the prevalence of FD in populations of patients suffering from chronic&#xD;
      pains of unknown origin.&#xD;
&#xD;
      The diagnosis of FD will be performed by standard procedures following international&#xD;
      recommendations. These require the search for a deficiency of alphagalactosidase A activity&#xD;
      on leucocytes in males and genetic analysis of the GLA gene in females (Lidove et al. 2007).&#xD;
&#xD;
      The patients in whom the diagnosis of FD is established during this study, will be call in&#xD;
      for an additional visit in the Investigating Centre in order to confirm the diagnosis and&#xD;
      propose suitable assessment and care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of Fabry disease in one patient suffering from chronic pains</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Pain</condition>
  <condition>Fabry's Disease</condition>
  <arm_group>
    <arm_group_label>Diagnosis of Fabry disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood sampling for biological and genetic analysis</intervention_name>
    <description>Clinical examination&#xD;
Blood sampling for biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females.</description>
    <arm_group_label>Diagnosis of Fabry disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients of both sex&#xD;
&#xD;
          -  aged from 6 to 65&#xD;
&#xD;
          -  with chronic pains of unknown aetiology including:&#xD;
&#xD;
          -  acroparesthesias&#xD;
&#xD;
          -  and/or pain crises evolving more than 3 months&#xD;
&#xD;
          -  continued neuropathic evolving more than 3 months&#xD;
&#xD;
          -  and/or multiple pains evolving more than 3 months&#xD;
&#xD;
          -  and/or recurrent abdominal crises of pain who come for a clinical visit in the Centre&#xD;
             Douleurs Chroniques in the CHU of Bordeaux.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic pain of known cause&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginie DOUSSET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Douleurs Chroniques, Hopital Pellegrin</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2010</study_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic pains</keyword>
  <keyword>unknown aetiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

